2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European…
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People and the Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction is presented.
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European…
2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of…
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo.
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
- J. Perk, G. Backer, Developed with the special contribution of the European Asso Rehabilitation
- MedicineInternational Journal of Behavioral Medicine
- 1 July 2012
Atherosclerotic cardiovascular disease is a chronic disorder developing insidiously thoughout life and usually progressing to an advanced stage by the time symptoms occur, thereby remaining the leading somatic cause of loss of productivity.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.
Eplerenone in patients with systolic heart failure and mild symptoms.
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
Exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization, and in key secondary clinical end points.